148 related articles for article (PubMed ID: 38586950)
1. Design and Synthesis of Novel Macrocyclic Derivatives as Potent and Selective Cyclin-Dependent Kinase 7 Inhibitors.
Niu P; Tao Y; Lin G; Xu H; Meng Q; Yang K; Huang W; Song M; Ding K; Ma D; Fan M
J Med Chem; 2024 Apr; 67(8):6099-6118. PubMed ID: 38586950
[TBL] [Abstract][Full Text] [Related]
2. Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study.
Hazel P; Kroll SH; Bondke A; Barbazanges M; Patel H; Fuchter MJ; Coombes RC; Ali S; Barrett AG; Freemont PS
ChemMedChem; 2017 Mar; 12(5):372-380. PubMed ID: 28125165
[TBL] [Abstract][Full Text] [Related]
3. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity.
Ali S; Heathcote DA; Kroll SH; Jogalekar AS; Scheiper B; Patel H; Brackow J; Siwicka A; Fuchter MJ; Periyasamy M; Tolhurst RS; Kanneganti SK; Snyder JP; Liotta DC; Aboagye EO; Barrett AG; Coombes RC
Cancer Res; 2009 Aug; 69(15):6208-15. PubMed ID: 19638587
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).
Poulsen A; William A; Blanchard S; Nagaraj H; Williams M; Wang H; Lee A; Sun E; Teo EL; Tan E; Goh KC; Dymock B
J Mol Model; 2013 Jan; 19(1):119-30. PubMed ID: 22820730
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel potent CDK7 inhibitors.
Zhang H; Lin G; Jia S; Wu J; Zhang Y; Tao Y; Huang W; Song M; Ding K; Ma D; Fan M
Bioorg Chem; 2024 Jul; 148():107456. PubMed ID: 38761706
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel macrocyclic derivatives as potent and selective cyclin-dependent kinase 2 inhibitors.
Niu P; Tao Y; Meng Q; Huang Y; Li S; Ding K; Ma D; Ye Z; Fan M
Bioorg Med Chem; 2024 Apr; 104():117711. PubMed ID: 38583237
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent kinase 7 inhibitors in cancer therapy.
Wang M; Wang T; Zhang X; Wu X; Jiang S
Future Med Chem; 2020 May; 12(9):813-833. PubMed ID: 32208930
[TBL] [Abstract][Full Text] [Related]
8. Discovery of macrocyclic CDK2/4/6 inhibitors with improved potency and DMPK properties through a highly efficient macrocyclic drug design platform.
Meng F; Liu J; Cao Z; Yu J; Steurer B; Yang Y; Wang Y; Cai X; Zhang M; Ren F; Aliper A; Ding X; Zhavoronkov A
Bioorg Chem; 2024 May; 146():107285. PubMed ID: 38547721
[TBL] [Abstract][Full Text] [Related]
9. Characterization of new highly selective pyrazolo[4,3-d]pyrimidine inhibitor of CDK7.
Kovalová M; Havlíček L; Djukic S; Škerlová J; Peřina M; Pospíšil T; Řezníčková E; Řezáčová P; Jorda R; Kryštof V
Biomed Pharmacother; 2023 May; 161():114492. PubMed ID: 36931035
[TBL] [Abstract][Full Text] [Related]
10. A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022).
Kovalová M; Baraka JP; Mik V; Jorda R; Luo L; Shao H; Kryštof V
Expert Opin Ther Pat; 2023 Feb; 33(2):67-87. PubMed ID: 36975020
[TBL] [Abstract][Full Text] [Related]
11. Discovery and optimization of thieno[3,2-d]pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7.
Zhang H; Lin G; Jia S; Zhang Y; Wu J; Tao Y; Huang W; Song M; Ding K; Ma D; Fan M
Eur J Med Chem; 2024 Jan; 263():115955. PubMed ID: 38000213
[TBL] [Abstract][Full Text] [Related]
12. Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype.
Olson CM; Liang Y; Leggett A; Park WD; Li L; Mills CE; Elsarrag SZ; Ficarro SB; Zhang T; Düster R; Geyer M; Sim T; Marto JA; Sorger PK; Westover KD; Lin CY; Kwiatkowski N; Gray NS
Cell Chem Biol; 2019 Jun; 26(6):792-803.e10. PubMed ID: 30905681
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors.
Tao ZF; Wang L; Stewart KD; Chen Z; Gu W; Bui MH; Merta P; Zhang H; Kovar P; Johnson E; Park C; Judge R; Rosenberg S; Sowin T; Lin NH
J Med Chem; 2007 Apr; 50(7):1514-27. PubMed ID: 17352464
[TBL] [Abstract][Full Text] [Related]
14. CDK7 inhibitors as anticancer drugs.
Sava GP; Fan H; Coombes RC; Buluwela L; Ali S
Cancer Metastasis Rev; 2020 Sep; 39(3):805-823. PubMed ID: 32385714
[TBL] [Abstract][Full Text] [Related]
15. Recent advances on CDK inhibitors: An insight by means of in silico methods.
Tutone M; Almerico AM
Eur J Med Chem; 2017 Dec; 142():300-315. PubMed ID: 28802482
[TBL] [Abstract][Full Text] [Related]
16. Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery.
Fisher RP
Transcription; 2019 Apr; 10(2):47-56. PubMed ID: 30488763
[TBL] [Abstract][Full Text] [Related]
17. Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7.
Hu S; Marineau JJ; Rajagopal N; Hamman KB; Choi YJ; Schmidt DR; Ke N; Johannessen L; Bradley MJ; Orlando DA; Alnemy SR; Ren Y; Ciblat S; Winter DK; Kabro A; Sprott KT; Hodgson JG; Fritz CC; Carulli JP; di Tomaso E; Olson ER
Cancer Res; 2019 Jul; 79(13):3479-3491. PubMed ID: 31064851
[TBL] [Abstract][Full Text] [Related]
18. Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer.
Wang BY; Liu QY; Cao J; Chen JW; Liu ZS
Drug Des Devel Ther; 2016; 10():1181-9. PubMed ID: 27042010
[TBL] [Abstract][Full Text] [Related]
19. Macrocyclic aminopyrimidines as multitarget CDK and VEGF-R inhibitors with potent antiproliferative activities.
Lücking U; Siemeister G; Schäfer M; Briem H; Krüger M; Lienau P; Jautelat R
ChemMedChem; 2007 Jan; 2(1):63-77. PubMed ID: 17131463
[TBL] [Abstract][Full Text] [Related]
20. Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy.
Liang H; Du J; Elhassan RM; Hou X; Fang H
Expert Opin Investig Drugs; 2021 Jan; 30(1):61-76. PubMed ID: 33183110
[No Abstract] [Full Text] [Related]
[Next] [New Search]
